US Stock MarketDetailed Quotes

FEMY Femasys

Watchlist
  • 1.0900
  • -0.0300-2.68%
Close Oct 11 16:00 ET
  • 1.1000
  • +0.0100+0.92%
Post 19:28 ET
24.23MMarket Cap-1297P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Oct 2 07:40
    NEWS
    $Femasys (FEMY.US)$
    Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
    ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribut...
    Trytosaveabit
    Trytosaveabit
    Sep 11 07:36
    Update
    $Femasys (FEMY.US)$ Reuters
    ·3 mins ago
    Femasys Secures Strategic Distribution Partnerships for Commercialization of Femaseed® for Over $1.3M in Spanish Market
    Jaguar8
    Jaguar8
    Sep 11 07:32
    NEWS
    $Femasys (FEMY.US)$
    Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
    Share on Reddit
    Share on Facebook
    09/11/2024 - 05:30 AM
    Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products
    ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of wome...
    IAM
    IAM
    Sep 9 14:40
    $Femasys (FEMY.US)$  with good news and went red.  ?  🥴
    2
    Jaguar8
    Jaguar8
    Sep 9 07:34
    NEWS
    $Femasys (FEMY.US)$
    Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
    ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announced it has received 510(k) clearance from the United States Food and Drug Ad...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data